Kronos Bio (Nasdaq: KRON) is to cut around 19% of its staff as part of a plan to extend its cash runway into 2026.
The oncology specialist said it was making the decision in order to “optimize its resource allocation” after positive preliminary safety and efficacy data from a Phase I/II trial of KB-0742, a CDK9 blocker.
The candidate is in development for the treatment of certain solid tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze